CAR T-Cell Therapy for ALL

December 9, 2014
Jae Park, MD

Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses CAR T-cell therapy for the treatment of acute lymphoblastic leukemia.

Clinical Pearls

Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses CAR T-cell therapy for the treatment of acute lymphoblastic leukemia.

  • Adult patients with relapsed ALL have a poor prognosis — overall survival is less than 10%.
  • This CD-19-targeted CAR modified T-cell therapy elicited an 80% complete remission rate.
  • The vast majority of these responses were MRD-negative.

<<<

Go back to the ASH conference page